内源性大麻素系统用于骨质疏松症预防与治疗的研究进展  

Research progress of endocannabinoid system for prevention and treatment of osteoporosis

作　　者：王蕾[1] 杨涛 耿立成[1] 孙天威[2] WANG Lei;YANG Tao;GENG Licheng;SUN Tianwei(Department of Anesthesiology,Tianjin Union Medical Center,Tianjin 300121,China;Department of Spine Surgery,Tianjin Union Medical Center,Tianjin 300121,China)

机构地区：[1]天津市人民医院麻醉科,300121 [2]天津市人民医院脊柱外科

出　　处：《天津医药》2023年第9期1020-1024,共5页Tianjin Medical Journal

基　　金：天津市科技计划项目(22JCZDJC00250)。

摘　　要：骨质疏松症(OP)是一种以骨量减少和骨组织微结构改变为特征的全身性骨骼疾病,其发病率呈逐年上升趋势,已经成为严重的公共健康隐患。成骨细胞和破骨细胞介导的骨代谢失衡是OP的重要发病机制。内源性大麻素系统(ECS)广泛分布于骨组织中,参与调节成骨细胞及破骨细胞的多种生物学功能,可能是OP的潜在治疗靶点,靶向ECS进行深入研究能够为OP的临床治疗提供新的理论依据。就ECS在调控OP发病过程中的具体作用进行了综述。Osteoporosis(OP)is a kind of systemic bone disease characterized by reduced bone mass and changes of bone microstructure.The incidence rate of OP has been increasing gradually year by year,which has become a severe public health issue.The imbalance of bone metabolism mediated by osteoblasts and osteoclast is an important pathogenesis of OP.The endocannabinoid system(ECS)is widely distributed in bone tissue and participates in regulating multiple biological effects of osteoblasts and osteoclasts,suggesting that ECS may be a potential treatment target of OP.Further study on targeting ESC can provide a new theoretical basis for the clinical treatment of OP.This article reviews the specific role of ECS in regulating the pathogenesis of OP.

关 键 词：骨质疏松 受体 大麻酚 大麻素受体调节剂 成骨细胞 骨代谢 

分 类 号：R681.4[医药卫生—骨科学] R614[医药卫生—外科学] R285[医药卫生—临床医学]